TCGX Acquisition Corp. Class A Ordinary Shares TCGX

Blank-check company formed for the purpose of effecting a merger, acquisition, or similar business c...

Price10.05

Market Cap113.49 M

Float8.63 M

CountryUS

SectorFinancial Services

ExchangeNASDAQ

Overview Filings Insights Dilution News Transcripts

Search in Documents

Open in Studio Login

TCGX TCGX Acquisition Corp. Class A Ordinary Shares

Sector

Financial Services

Industry

Shell Companies

Country

Exchange

NASDAQ

Vol Avg.

115.07 K

Inst Own

0.000%

Float & OS

8.63 M / 11.3 M

Cash/Shr

-

Market Cap & Ev

113.49 M / N/A

Short Interest

0.6%

Borrow Rate

42.3754%

Days to Cover

7.36

Overall Offering Risk

Warrant Exercise Risk

Research Report

Customize research

Recent Articles (6)

TriGemX Bio Appoints Daniel Lynch as Chairman of the TriGemX Bio Board of Directors

New

Business Wire

Nov 9, 2026, 7:00 AM

TriGemX Bio and TCGX Acquisition Corp. Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination

Business Wire

Nov 2, 2026, 6:00 AM

TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, a Potential First-in-Class Treatment for Migraine

Business Wire

Oct 19, 2026, 7:00 AM

TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination Agreement to Create Publicly Listed Company to Develop Elismetrep, A Potential First-in-Class Treatment for Migraine

Business Wire

Oct 19, 2026, 7:00 AM

TCGX Acquisition Corp. Announces Completion of its Initial Public Offering

Business Wire

Aug 6, 2026, 4:05 PM

TCGX Acquisition Corp. Announces Pricing of $75,000,000 Initial Public Offering

Business Wire

Aug 4, 2026, 7:10 PM

Recent Filings

	Type	Title	Date Released
	10-Q	Form 10-Q New	Nov 9, 2026, 4:05 PM
	425	Form 425 New	Nov 9, 2026, 9:08 AM
	425	Form 425	Nov 2, 2026, 4:03 PM
	425	Form 425	Oct 19, 2026, 5:12 PM
	425	Form 425	Oct 19, 2026, 5:11 PM
	425	Form 425	Oct 19, 2026, 9:25 AM
	8-K	TriGemX Bio and TCGX Acquisition Corp. Announce Business Combination to Form Publicly Traded Company Focused on Migraine Treatment	Oct 19, 2026, 9:20 AM
	10-Q	Form 10-Q	Sep 10, 2026, 4:08 PM
	SCHEDULE 13G	RA CAPITAL MANAGEMENT, L.P. (Filed by)	Aug 13, 2026, 4:15 PM
	SCHEDULE 13G	BIOTECHNOLOGY VALUE FUND L P (Filed by)	Aug 12, 2026, 4:55 PM
	8-K	TCGX Acquisition Corp. Announces Closing of Initial Public Offering	Aug 12, 2026, 4:46 PM
	4	Yu Chen-Ming (Reporting)	Aug 6, 2026, 5:05 PM

Earnings

No earnings availableNo calendar earnings available for TCGX